Forma Therapeutics


FORMA Therapeutic’s novel approach to accessing high value drug targets, many of which pose significant challenges to conventional discovery approaches, leverages the integration of its innovative drug discovery technologies and oncology expertise for the generation of novel small molecule drug candidates with qualified cellular mechanisms of action. FORMA is building a robust pipeline of transformative cancer therapeutics directed in areas such as tumor metabolism, epigenetics and protein-protein interactions. FORMA has established collaborations with multiple global pharma companies to develop first-in-class and best-in-class therapeutic agents.

Other investors include: Novartis Ventures, BioOne, and Cubist Pharmaceuticals.